PE20040893A1 - DERIVADOS DE INDOL O DERIVADOS DE BENCIMIDAZOL PARA MODULAR IkB QUINASA - Google Patents

DERIVADOS DE INDOL O DERIVADOS DE BENCIMIDAZOL PARA MODULAR IkB QUINASA

Info

Publication number
PE20040893A1
PE20040893A1 PE2003000772A PE2003000772A PE20040893A1 PE 20040893 A1 PE20040893 A1 PE 20040893A1 PE 2003000772 A PE2003000772 A PE 2003000772A PE 2003000772 A PE2003000772 A PE 2003000772A PE 20040893 A1 PE20040893 A1 PE 20040893A1
Authority
PE
Peru
Prior art keywords
derivatives
alkyl
benzhimidazole
modular
ikb kinase
Prior art date
Application number
PE2003000772A
Other languages
English (en)
Inventor
Gerhard Jaehne
Olaf Ritzeler
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of PE20040893A1 publication Critical patent/PE20040893A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • AIDS & HIV (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA I DONDE X Y M SON CADA UNO N, CH; R1 Y R11 SON CADA UNO H, HALOGENO, ALQUILO C1-C4, -CN, ENTRE OTROS; R2 ES HETEROARILO, -COOH, -COO(ALQUILO C1-C4), ENTRE OTROS; R3 ES H, ALQUILO C1-C4; R4 ES ARILO O HETEROARILO DEL GRUPO PIRROL, FURANO, TIOFENO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: N-[(S)-2-DIFENILAMINO-1-(5-OXO-4,5-DIHIDRO[1,3,4]OXADIAZOL-2-IL)ETIL]-2-(2-METILAMINOPIRIMIDIN-4-IL)-1H-INDOL-5-CARBOXAMIDA Y N-{1-CARBAMOIL-2-[(4-FLUOROFENIL)PIRIDIN-2-ILAMINO]ETIL}-2-(2-METILAMINOPIRIMIDIN-4-IL)-1H-INDOL-5-CARBOXAMIDA; ENTRE OTROS. SE REFIERE TAMBIEN A UN PRODUCTO FARMACEUTICO EN EL CUAL DICHOS COMPUESTOS SON INHIBIDORES DE IkB QUINASA UTILES EN EL TRATAMIENTO DE ARTRITIS REUMATOIDE, ARTROPATIAS OSTEOARTRITIS, DIABETES TIPO II, ENTRE OTROS
PE2003000772A 2002-08-17 2003-08-05 DERIVADOS DE INDOL O DERIVADOS DE BENCIMIDAZOL PARA MODULAR IkB QUINASA PE20040893A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10237722A DE10237722A1 (de) 2002-08-17 2002-08-17 Indol- oder Benzimidazolderivate zur Modulation der IKappaB-Kinase

Publications (1)

Publication Number Publication Date
PE20040893A1 true PE20040893A1 (es) 2004-12-21

Family

ID=31968974

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2003000772A PE20040893A1 (es) 2002-08-17 2003-08-05 DERIVADOS DE INDOL O DERIVADOS DE BENCIMIDAZOL PARA MODULAR IkB QUINASA

Country Status (43)

Country Link
US (2) US7285560B2 (es)
EP (2) EP1530568B1 (es)
JP (1) JP4504812B2 (es)
KR (1) KR101162046B1 (es)
CN (1) CN1314683C (es)
AR (1) AR040975A1 (es)
AT (2) ATE493402T1 (es)
AU (1) AU2003263196B2 (es)
BR (1) BR0313562A (es)
CA (1) CA2498559C (es)
CO (1) CO5690586A2 (es)
CR (1) CR7668A (es)
CY (2) CY1111692T1 (es)
DE (2) DE10237722A1 (es)
DK (2) DK1530568T3 (es)
EC (1) ECSP055612A (es)
ES (2) ES2387954T3 (es)
HK (1) HK1079509A1 (es)
HN (1) HN2003000249A (es)
HR (1) HRP20050042B1 (es)
IL (1) IL166785A0 (es)
JO (1) JO2764B1 (es)
MA (1) MA27382A1 (es)
ME (1) MEP60608A (es)
MX (1) MXPA05001314A (es)
MY (1) MY140074A (es)
NO (1) NO330981B1 (es)
NZ (1) NZ538296A (es)
OA (1) OA12908A (es)
PA (1) PA8580501A1 (es)
PE (1) PE20040893A1 (es)
PL (1) PL374229A1 (es)
PT (2) PT1530568E (es)
RS (1) RS51902B (es)
RU (1) RU2318820C2 (es)
SI (2) SI2233483T1 (es)
SV (1) SV2004001599A (es)
TN (1) TNSN05045A1 (es)
TW (1) TWI290552B (es)
UA (1) UA78591C2 (es)
UY (1) UY27941A1 (es)
WO (1) WO2004022553A1 (es)
ZA (1) ZA200500322B (es)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19951360A1 (de) * 1999-10-26 2001-05-03 Aventis Pharma Gmbh Substituierte Indole
DE10237723A1 (de) * 2002-08-17 2004-07-08 Aventis Pharma Deutschland Gmbh Verwendung von IKappaB-Kinase Inhibitoren in der Schmerztherapie
DE10237722A1 (de) * 2002-08-17 2004-08-19 Aventis Pharma Deutschland Gmbh Indol- oder Benzimidazolderivate zur Modulation der IKappaB-Kinase
US8293751B2 (en) 2003-01-14 2012-10-23 Arena Pharmaceuticals, Inc. 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
AR045047A1 (es) * 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
KR20070011483A (ko) * 2004-05-12 2007-01-24 아벤티스 파마슈티칼스 인크. Ｉｋｂ 키나제 억제제로서의 실질적으로 순수한2-｛[2-(2-메틸아미노-피리미딘-4-일)-1ｈ-인돌-5-카르보닐]-아미노｝-3-(페닐피리딘-2-일-아미노)-프로피온산
TW200616967A (en) 2004-06-24 2006-06-01 Smithkline Beecham Corp Novel indazole carboxamides and their use
DE102004033406A1 (de) * 2004-07-10 2006-02-16 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung der enantiomeren Formen von 2,3-Diaminopropionsäurederivaten
TW200626142A (en) 2004-09-21 2006-08-01 Glaxo Group Ltd Chemical compounds
DOP2006000010A (es) * 2005-01-10 2006-07-31 Arena Pharm Inc Procedimiento para preparar eteres aromáticos
WO2006076318A1 (en) * 2005-01-12 2006-07-20 Aventis Pharmaceuticals Inc. Monopotassium salt of an ikb kinase inhibitor
US20070142417A1 (en) * 2005-05-11 2007-06-21 Aventis Pharmaceuticals Inc Substantially Pure 2-{[2-(2-Methylamino-Pyrimidin-4-YL)-1H-Indole-5-Carbonyl]-Amino}-3-Phenylpyridin-2-YL-Amino)-Propionic Acid as an IkB Kinase Inhibitor
DE102005025225A1 (de) 2005-06-01 2006-12-07 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung von 2-(2-Amino-pyrimidin-4-yl)-1H-indol-5-carbonsäure-derivaten
BRPI0611674A2 (pt) 2005-06-30 2009-04-28 Smithkline Beecham Corp compostos quÍmicos
US8063071B2 (en) 2007-10-31 2011-11-22 GlaxoSmithKline, LLC Chemical compounds
US8088928B2 (en) * 2005-08-04 2012-01-03 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
US7855289B2 (en) * 2005-08-04 2010-12-21 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
CA2618360C (en) 2005-08-04 2015-06-09 Sirtris Pharmaceuticals, Inc. Benzothiazoles and thiazolopyridines as sirtuin modulators
US8093401B2 (en) * 2005-08-04 2012-01-10 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
EP1931322B1 (en) 2005-09-07 2012-08-15 Merck Serono SA Ikk inhibitors for the treatment of endometriosis
JP2009001495A (ja) * 2005-10-13 2009-01-08 Taisho Pharmaceutical Co Ltd ２−アリール−ベンゾイミダゾール−５−カルボキサミド誘導体
WO2008017381A1 (de) 2006-08-08 2008-02-14 Sanofi-Aventis Arylaminoaryl-alkyl-substituierte imidazolidin-2,4-dione, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und ihre verwendung
PE20081889A1 (es) 2007-03-23 2009-03-05 Smithkline Beecham Corp Indol carboxamidas como inhibidores de ikk2
TW200916472A (en) * 2007-06-20 2009-04-16 Sirtris Pharmaceuticals Inc Sirtuin modulating compounds
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US20110039847A1 (en) * 2007-11-01 2011-02-17 Sirtris Pharmaceuticals, Inc Amide derivatives as sirtuin modulators
US20110009381A1 (en) * 2007-11-08 2011-01-13 Sirtis Pharmaceuticals, Inc. Solubilized thiazolopyridines
US8470841B2 (en) 2008-07-09 2013-06-25 Sanofi Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
MY160006A (en) 2008-12-19 2017-02-15 Sirtris Pharmaceuticals Inc Thiazolopyridine sirtuin modulating compounds
SG174146A1 (en) * 2009-02-27 2011-10-28 Enanta Pharm Inc Hepatitis c virus inhibitors
US8354539B2 (en) 2009-03-10 2013-01-15 Glaxo Group Limited Indole derivatives as IKK2 inhibitors
CA2771278A1 (en) 2009-08-26 2011-03-03 Sanofi Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
CN108558740B (zh) 2010-01-27 2021-10-19 艾尼纳制药公司 S1p1受体调节剂及其盐的制备方法
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2563774B1 (en) * 2010-04-27 2014-03-12 Hutchison Medipharma Limited Pyrimidinyl indole compounds
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
CN103209961A (zh) 2010-08-12 2013-07-17 赛诺菲 用于制备2,3-二氨基丙酸衍生物的对映异构体形式的方法
AU2011305525B2 (en) 2010-09-22 2016-08-18 Arena Pharmaceuticals, Inc. Modulators of the GPR119 receptor and the treatment of disorders related thereto
TW201242962A (en) * 2010-12-01 2012-11-01 Sumitomo Chemical Co Pyrimidine compound and use for pest control thereof
EP2683702B1 (de) 2011-03-08 2014-12-24 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8809325B2 (en) 2011-03-08 2014-08-19 Sanofi Benzyl-oxathiazine derivatives substituted with adamantane and noradamantane, medicaments containing said compounds and use thereof
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8901114B2 (en) 2011-03-08 2014-12-02 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
EP2683703B1 (de) 2011-03-08 2015-05-27 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683701B1 (de) 2011-03-08 2014-12-24 Sanofi Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
SG10201402860QA (en) 2011-07-27 2014-08-28 Astrazeneca Ab 2 - (2, 4, 5 - substituted -anilino) pyrimidine derivatives as egfr modulators useful for treating cancer
DK2748147T3 (da) * 2011-08-25 2017-11-13 St Jude Children's Res Hospital Substitueret 2-alkyl-1-oxo-n-phenyl-3-heteroaryl-1,2,3,4-tetrahydroisoquinolin-4-carboxamider til antimalaria-terapier
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
ES2612217T3 (es) 2011-12-06 2017-05-12 Sanofi Formas cristalinas de [(S)-1-carbamoil-2-(fenil-pirimidin-2-il-amino)-etil]-amida del ácido 2-(2-metilamino-pirimidin-4-il)-1H-indol-5-carboxílico
EA202092034A3 (ru) * 2012-01-27 2021-02-26 Астразенека Аб Производные 2-(2,4,5-замещенного анилино)пиримидина в качестве модуляторов egfr, полезных для лечения рака
KR101493877B1 (ko) 2013-03-29 2015-02-16 농업회사법인 주식회사 생명의나무 스피나스테롤 당 유도체를 포함하는 골 질환 예방 또는 치료용 약학 조성물
EP2805705B1 (en) 2013-05-23 2016-11-09 IP Gesellschaft für Management mbH Packaging with one or more administration units comprising a sodium salt of (R)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexyl-1 H-imidazol-4-yl)-propionic acid
EP2905282A1 (en) * 2014-02-05 2015-08-12 AXXAM S.p.A. Substituted thiazole or oxazole as P2X7 receptor antagonists
JP6553179B2 (ja) * 2014-07-03 2019-07-31 サノフイＳａｎｏｆｉ 骨関節炎に関連する疼痛の治療で使用するための２−（２−メチルアミノ−ピリミジン−４−イル）−１ｈ−インドール−５−カルボン酸［（ｓ）−１−カルバモイル−２−（フェニル−ピリミジン−２−イル−アミノ）−エチル］−アミド
WO2016112075A1 (en) 2015-01-06 2016-07-14 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the s1p1 receptor
BR112017027656B1 (pt) 2015-06-22 2023-12-05 Arena Pharmaceuticals, Inc. Hábito cristalino de placa livre de sal de l-arginina de ácido (r)-2-(7-(4- ciclopentil-3-(trifluorometil)benzilóxi)- 1,2,3,4-tetra-hidrociclo-penta[b]indol-3- il)acético, composição farmacêutica que o compreende, seus usos e método de preparação do mesmo
EP3290416A1 (en) * 2016-08-31 2018-03-07 AXXAM S.p.A. Substituted n-[2-(4-phenoxypiperidin-1-yl)-2-(1,3-thiazol-5-yl)ethyl]benzamide and n-[2-(4-benzyloxypiperidin-1-yl)-2-(1,3-thiazol-5-yl)ethyl]benzamide derivatives and their use as p2x7 receptor antagonist
CN106588803A (zh) * 2016-11-16 2017-04-26 西南科技大学 一种制备5‑乙酰基异噁唑的新方法
CN108299302A (zh) * 2017-01-11 2018-07-20 西南科技大学 一种制备3-乙酰基吡唑的新方法
AU2018220521A1 (en) 2017-02-16 2019-09-05 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of primary biliary cholangitis
AU2021214148A1 (en) * 2020-01-30 2022-07-14 Anima Biotech Inc. Collagen 1 translation inhibitors and methods of use thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0664792B1 (en) 1992-10-14 2000-01-05 Merck & Co. Inc. Fibrinogen receptor antagonists
GB9225141D0 (en) 1992-12-01 1993-01-20 Smithkline Beecham Corp Chemical compounds
IT1275433B (it) * 1995-05-19 1997-08-07 Smithkline Beecham Farma Derivati di diarildiammine
PL206826B1 (pl) * 1999-06-23 2010-09-30 Sanofi Aventis Deutschland Podstawione benzimidazole
DE19951360A1 (de) * 1999-10-26 2001-05-03 Aventis Pharma Gmbh Substituierte Indole
HUP0304045A3 (en) 2001-02-01 2005-05-30 Bristol Myers Squibb Company P Use of ikb-kinase inhibitors for treating of inflammatory and immune diseases and pharmaceutical compositions containing them
DE10237723A1 (de) * 2002-08-17 2004-07-08 Aventis Pharma Deutschland Gmbh Verwendung von IKappaB-Kinase Inhibitoren in der Schmerztherapie
US7462638B2 (en) * 2002-08-17 2008-12-09 Sanofi-Aventis Deutschland Gmbh Use of IκB-kinase inhibitors in pain therapy
DE10237722A1 (de) * 2002-08-17 2004-08-19 Aventis Pharma Deutschland Gmbh Indol- oder Benzimidazolderivate zur Modulation der IKappaB-Kinase
US7046741B2 (en) * 2004-04-16 2006-05-16 Data Flow Technologies, Inc. Single and multiple sinewave modulation and demodulation techniques, apparatus, and communications systems

Also Published As

Publication number Publication date
HRP20050042B1 (hr) 2013-09-30
ZA200500322B (en) 2006-07-26
MA27382A1 (fr) 2005-06-01
EP1530568A1 (de) 2005-05-18
ECSP055612A (es) 2005-04-18
UY27941A1 (es) 2004-03-31
CN1675196A (zh) 2005-09-28
US20070244139A1 (en) 2007-10-18
JP4504812B2 (ja) 2010-07-14
DK1530568T3 (da) 2011-04-18
ES2358795T3 (es) 2011-05-13
RS20050104A (en) 2007-06-04
TWI290552B (en) 2007-12-01
HK1079509A1 (en) 2006-04-07
CY1111692T1 (el) 2015-10-07
NO20051337L (no) 2005-05-03
US20050197353A1 (en) 2005-09-08
CA2498559C (en) 2012-01-24
OA12908A (en) 2006-10-13
DE10237722A1 (de) 2004-08-19
RU2005107418A (ru) 2005-08-27
KR20050058338A (ko) 2005-06-16
TNSN05045A1 (en) 2007-05-14
ES2387954T3 (es) 2012-10-04
CY1112991T1 (el) 2016-04-13
AU2003263196B2 (en) 2009-01-22
PT2233483E (pt) 2012-07-20
ATE557018T1 (de) 2012-05-15
AR040975A1 (es) 2005-04-27
EP1530568B1 (de) 2010-12-29
NO330981B1 (no) 2011-08-29
DE50313372D1 (de) 2011-02-10
IL166785A0 (en) 2006-01-15
HN2003000249A (es) 2008-08-06
CA2498559A1 (en) 2004-03-18
SV2004001599A (es) 2004-02-26
HRP20050042A2 (en) 2006-03-31
PL374229A1 (en) 2005-10-03
TW200418832A (en) 2004-10-01
RS51902B (sr) 2012-02-29
EP2233483B1 (de) 2012-05-09
CO5690586A2 (es) 2006-10-31
RU2318820C2 (ru) 2008-03-10
KR101162046B1 (ko) 2012-07-04
ATE493402T1 (de) 2011-01-15
CN1314683C (zh) 2007-05-09
PA8580501A1 (es) 2004-04-23
SI2233483T1 (sl) 2012-08-31
MEP60608A (en) 2011-05-10
MY140074A (en) 2009-11-30
DK2233483T3 (da) 2012-08-20
UA78591C2 (en) 2007-04-10
WO2004022553A1 (de) 2004-03-18
JO2764B1 (en) 2014-03-15
PT1530568E (pt) 2011-02-23
US7285560B2 (en) 2007-10-23
MXPA05001314A (es) 2005-04-28
SI1530568T1 (sl) 2011-05-31
NZ538296A (en) 2007-03-30
EP2233483A1 (de) 2010-09-29
JP2005539054A (ja) 2005-12-22
US8778955B2 (en) 2014-07-15
AU2003263196A1 (en) 2004-03-29
BR0313562A (pt) 2006-06-13
CR7668A (es) 2009-03-11

Similar Documents

Publication Publication Date Title
PE20040893A1 (es) DERIVADOS DE INDOL O DERIVADOS DE BENCIMIDAZOL PARA MODULAR IkB QUINASA
RU2009115963A (ru) Производные оксадиазола, обладающие противовоспалительными и иммунодепрессантными свойствами
PE20030940A1 (es) Derivados de piridina y pirimidina
CO5700824A2 (es) Nuevos compuestos heterociclicos utiles para el tratamiento de desordenes inflamatorios y alergicos: proceso para su preparacion y composiciones farmaceuticas que los contienen
CO5550421A2 (es) Derivados de indol utiles para el tratamiento de enfermeda- des
AR058403A1 (es) PIRIMIDINILOXI Y PIRIDINILOXI UREAS SUSTITUíDAS COMO INHIBIDORES DE PROTEíNA QUINASAS, COMPOSICIONES FARMACÉUTICAS QUE LAS CONTIENEN Y SU USO EN LA PREPARACIoN DE UN MEDICAMENTO PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR LA ACTIVIDAD BASAL DE B-RAF.
PE20130012A1 (es) Derivados de pirazol como inhibidores de jak
AR039648A1 (es) Compuestos de aril cetona pirrolo triazina utiles como inhibidores de cinasa y las composiciones farmaceuticas que las contienen
NZ533310A (en) Benzimidazoles useful as protein kinase inhibitors
EA200600364A1 (ru) Производные (тио)карбамоилциклогексана в качестве антагонистов d/dрецептора
TW200612936A (en) Indole derivatives
NO20033145D0 (no) Purinderivater som purinergiske reseptorantagonister
EA200870192A1 (ru) Новые серосодержащие производные циклической мочевины, их получение и их фармацевтическое применение в качестве ингибиторов киназ
UY29312A1 (es) Piperazin-1-carboxamidas n,4,sustituidas y sus derivados, composiciones que los contienen, procedimientos de preparación y aplicaciones
DK1412354T3 (da) Derivater af triazolylimidazopyridin og af triazolylpurinerne, der er egnede som ligander for adenosin A2a?-receptoren og deres anvendelse som medikamenter
EA201000101A1 (ru) Производные пиримидина 934
NO20061981L (no) Arylindenopyridiner og arylindenopyridiner og deres anvendelse som adenosin A2A reseptoragonist
PE20091243A1 (es) Compuesto heterociclico fusionado
PE20070212A1 (es) Heterociclos de 1,4-dihidropiridina-condensados, procesos para preparar los mismos, uso y composiciones que los contienen
AR035945A1 (es) Derivados de piperacina, su uso en la preparacion de medicamentos, procedimiento para la preparacion de dichos compuestos, composiciones farmaceuticas que comprenden dichos compuestos, y metodo para preparar dichas composiciones
PE20061078A1 (es) Derivados de piridotienopirimidina como inhibidores de la fosfodiesterasa 4 (pde4)
NO20075617L (no) 4-fenyl-5-okso-1,4,5,6,7,8-heksahydrokinolinderivater for behandling av infertilitet
DE60014404D1 (de) Aminobenzophenone als inhibitoren von il-1beta und tnf-alpha
AR046077A1 (es) Derivados de n4- oxicarbonilcitimidina, procedimientos de eleaboracion y usos de los mismos
DE60014394D1 (de) Aminobenzophenone als inhibitoren von il-1beta und tnf-alpha

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed